Axitinib

본문 바로가기


Home > Product > Axitinib
Selling leads
Axitinib
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Axitinib (axitinib) is a multi-target small molecule inhibitor, with its main targets being VEGFR, Kit, PDGFR, and RET. The currently approved indication for marketing is the second-line treatment of advanced renal cell carcinoma. That is to say, after the failure of Sotan Chemicalbook treatment for advanced renal cell carcinoma, axitinib can be chosen for treatment. In addition to kidney cancer, this drug has also been attempted by patients for use in liver cancer, sarcoma, neuroendocrine tumors and other solid tumors that are recognized as sensitive to anti-angiogenic drugs and have rich blood supply to the tumor, and has achieved certain therapeutic effects.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top